PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

Launched by M.D. ANDERSON CANCER CENTER · Sep 17, 2021

Keywords

ClinConnect Summary

The PROSPECT trial is studying how certain biological factors in lung cancer can influence how well treatments work and how the disease behaves after treatment. Researchers want to understand how these factors might contribute to the cancer resisting therapy and help it grow back after it has been treated. By examining blood samples and tumor characteristics, the study aims to identify new potential targets for treatment and understand which factors might make the cancer harder to treat.

To participate in this trial, patients need to have stage I-IIIA non-small cell lung cancer (a common type of lung cancer) and must have had surgery to remove the tumor, with or without prior chemotherapy (medicines used to kill cancer cells). The study welcomes all eligible patients, regardless of gender or smoking history. Participants can expect to provide information about their health and treatment history, and their results may help improve future treatment strategies for lung cancer. There are no specific exclusion criteria, making it accessible for many patients facing this diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC) and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard treatment, and have a information of demographics, smoking history, preoperative clinical data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse.
• • We will include the three major NSCLC histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma -
• • Exclusion Criteria: None